Page 7 - Zydus Cadila

Cadila Healthcare's Q4 PBT falls 14% to Rs 522 cr, total income rises 0.66%

Cadila has also been working on a DNA vaccine to fight Covid-19, which is currently in the animal testing stage

Covid-19 crisis: Made-in-India remdesivir may come by end of June

Currently, the drug is allowed for "restricted emergency use" on severely ill hospitalised Covid patients in India.

A glimmer of hope but...

...dexamethasone's positive effect on patients with severe Covid-19 infection and no effect on mild ones imply that it will not be used on a large scale

Zydus Cadila gets USFDA nod for generic antiviral drug, Atazanavir capsules

Atazanavir, an antiretroviral drug, is used to treat Human Immunodeficiency Virus (HIV-1) infection incombination with other antiretroviral drugs

Record jump in Covid-19 cases as tally crosses 125,000; 1st case in Sikkim

Active cases rose to 69,597, while 51,783 people have recovered and a patient has migrated, according to the ministry bulletin

Zydus Cadila supplies 30,000 COVID KAVACH Elisa test kits to ICMR

The kits, to be used for antibody detection of Covid-19, have been manufactured in collaboration (via technology transfer) with ICMR-NIV of Pune for surveillance purposes

Cadila to make India's first indigenous antibody test kit: Health Minister

The anti-SARS-Cov-2 human lgG ELISA kit has the advantage of testing 90 samples together in a single run of 2.5 hours

Not just bigwigs, Mid-rung local players join coronavirus vaccine race

With vaccines of some firms already in animal trial phase, developers say that if all goes well, India could have a vaccine by next year

Top 10 biz headlines: RIL results, FMCG mkt to see 'slowest' growth & more

Here are the top 10 business headlines this morning

India gears up for patient trials on 20 different drugs for Covid-19

Local pharma units have already started work on developing patented drugs, some have already approached regulator for approvals

Zydus Cadila gets final nod from USFDA to market generic seizures drug

The group now has 283 approvals and has so far filed over 386 abbreviated new drug applications

Coronavirus: Paracetamol prices jump 40% in India after shutdowns in China

The pharma industry could face shortages in finished drug formulations starting April if supplies aren't restored by the first week of next month

Zydus Cadila launches research programme to develop vaccine for coronavirus

The epidemic, which was detected last December, has claimed around 1,500 lives and infected over 66,000 people.

Zydus Cadila's Q3 PBT dips 32% to Rs 457 cr, revenue up marginally

Formulation sales in US up 16% sequentially to Rs 1,675 cr, rest-of-the-world biz consisting of multiple emerging markets grew by 21%

Zydus Cadila launches cheap oral anti-diabetic tablets after patent expires

With a patient population of almost 77 million diabetics in India, access to affordable therapy is vital for the effective management of the disease, the statement said.

Zydus Cadila gets tentative USFDA approval to market arthritis drug

The tablets will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad, Zydus Cadila said.

Zydus Cadila gets US FDA approval for generic muscle relaxing injection

The approval is for single-dose vials of Cisatracurium Besylate Injection USP with strengths of 10 mg/5 ml and 200 mg/20 ml

Zydus Cadila receives USFDA warning letter for its Moraiya facility

The company remains committed to patient safety and meeting the expectations of regulatory compliances, the Gujarat-based firm said.

USFDA issues warning letter for Cadila Healthcare's Moraiya facility

The formulation unit 45% of the firm's US sales; Cadila says letter does not impact its existing business in the United States for now

Zydus Cadila announces Q1 consolidated net profit of Rs 303.6 crore

The company saw its consolidated total revenue rise by 17.49 per cent to Rs 3,518.9 cr for the June quarter